Johnson & Johnson Pharmaceuticals Leader Jennifer Taubert to Retire
By Colin Kellaher
Johnson & Johnson said Jennifer Taubert, the head of its $60 billion pharmaceuticals business, is retiring after more than two decades with the drugmaker.
J&J on Tuesday said Tom Cavanaugh will succeed Taubert as executive vice president and worldwide chairman of innovative medicine on Sept. 1.
J&J's innovative-medicine business, which includes such blockbuster drugs as Darzalex, Tremfya and Stelara, accounted for $31.8 billion of the New Brunswick, N.J., company's first-half sales of $49.4 billion.
Taubert, who joined J&J in 2005, has been in her current post and member of the company's executive committee since 2018.
Cavanaugh, who joined J&J in 2017, currently serves as group chairman, North America, for innovative medicine and will also succeed Taubert on the executive committee, J&J said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 04, 2026 11:15 ET (15:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
3 Stocks to Invest In With More Room to Run
United States